Absolute risk low, but findings may help inform treatment decisions, say researchers Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today. Although the absolute risk is low, awareness of